Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Crinetics Pharmaceuticals, Inc. (CRNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 Development of CRN04777 Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO – August 8, 2023 – Crinetics Pharmaceuticals, Inc."
02/28/2023 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Paltusotine’s Phase 3 PATHFNDR-1study enrollment complete and topline data expected in 3Q 2023 - Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 - Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024 - Paltusotine’s Phase 2 study in carcinoid syndrome on track for data in 2H 2023 - CRN04894’s studies in Cushing’s disease and congenital adrenal hyperplasia commenced in 1Q 2023 SAN DIEGO – February 28, 2023"
11/14/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators SAN DIEGO – August 12, 2022"
05/12/2022 8-K Quarterly results
03/30/2022 8-K Investor presentation, Quarterly results
Docs: "CRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA Three months ended December 31, Twelve months ended December 31, STATEMENTS OF OPERATIONS DATA: 2021 2020 2021 2020 License revenues $ 1,078 $ — $ 1,078 $ — Grant revenues — — — 71 Total revenues 1,078 — 1,078 71 Operating expenses: Research and development 24,604 16,830 84,255 56,998 General and administrative 7,362 4,961 24,525 18,026 Total operating expenses 31,966 21,791 108,780 75,024 Loss from operations Total other income , net 94 150 61 1,141 Net loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average shares - basic and diluted 45,229 32,952 38,436 30,448 BALANCE SHEET DATA: December 31, 2021 December 31, 2020 Cash, cash equivalents and investments $ 333,707 $ 170,880 Working cap...",
"X X X X X"
11/05/2021 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update – Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts –"
05/06/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
11/06/2020 8-K Quarterly results
Docs: "Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of paltusotine in acromegaly patients. In October 2020, Crinetics reported topline results from its ACROBAT Edge and Evolve Phase 2 trial. The prespecified primary endpoint in Edge was achieved, showing that once-daily oral paltusotine maintained insulin-like growth factor-1 levels at Week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand depot of either octreotide or lanreotide monotherapy. This data showed that acromegaly patients switching to once-daily oral paltusotine from first-line injected depot monotherapies maintained IGF-1 levels previously achieved with octreotide or lanreotide. • Received Rare Pediatric Disease Designation for CRN04777 for the treatme..."
08/07/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
Docs: "Reported positive interim results for the ACROBAT Edge Phase 2 trial of paltusotine in acromegaly patients. In April 2020, Crinetics reported interim results from its ongoing ACROBAT Edge Phase 2 trial. Results as of the February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands. Interim results from an exploratory analysis of the first 13 patients who entered the Edge trial on octreotide or lanreotide depot monotherapy showed that patient IGF-1 levels were maintained after switching to once daily oral paltusotine when compared to IGF-1 levels achieved with prior depot therapy [mean change from ba..."
03/09/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
05/13/2019 8-K Quarterly results
Docs: "Dosed first patients in Phase 2 clinical trials of CRN00808 for acromegaly. In March 2019, Crinetics dosed the first patients in the ACROBAT EVOLVE and ACROBAT EDGE trials for CRN00808 in patients with acromegaly. The EVOLVE trial is a double-blind, placebo-controlled, randomized withdrawal study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, in patients with acromegaly that respond to octreotide LAR or lanreotide depot monotherapy. The EDGE trial is an open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 in patients with acromegaly that are treated with somatostatin analog based treatment regimens but do not respond completely to monot..."
03/13/2019 8-K Quarterly results
Docs: "Filed IND with the FDA. In August 2018, Crinetics filed its Investigational New Drug application for CRN00808 in acromegaly. • Completed initial public offering. In July 2018, Crinetics closed its initial public offering of 6,900,000 shares of common stock at a public offering price of $17.00 per share. Net proceeds were approximately $106.5 million, after deducting underwriting discounts, commissions, and offering expenses. • Awarded up to $3.2 million in SBIR grants for congenital hyperinsulinism and acromegaly. In June 2018, Crinetics was awarded up to approximately $3.2 million in Small Business Innovation Research grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to fund the continued research and develo..."
11/13/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update SAN DIEGO - November 13, 2018 - Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the quarter ended September 30, 2018 and provided an update on its corporate activities and product pipeline. “Following the success of our July 2018 initial public offering, the Crinetics team is on track for the initiation of our Phase 2 EVOLVE and Phase 2 EDGE clinical trials in early 2019 for our lead product candidate, CRN00808, in acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer..."
08/30/2018 8-K Quarterly results
Docs: "Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update SAN DIEGO - August 30, 2018 - Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the quarter ended June 30, 2018 and provided an update on its corporate activities and product pipeline. “Crinetics has made major progress in 2018 with the company's initial public offering, which raised net proceeds of $106.4 million,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “With our balance sheet substantially strengthened, we will focus on growing our operations and prep..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy